FDA Clears HDT Bio's First-in-Class HDT-321 for Crimean-Congo Hemorrhagic Fever Prevention
核心洞察
The FDA has cleared HDT Bio's IND application for HDT-321, a first-in-class prophylactic designed to protect against Crimean-Congo Hemorrhagic Fever (搜索), a tick-borne viral disease with mortality rates reaching 40%.
HDT-321 was developed using HDT Bio's proprietary LION™ delivery system (搜索) in collaboration with NIH/NIAID (搜索) and UTMB (搜索), with pre-clinical studies demonstrating protection against CCHF (搜索) in multiple animal models.
The development is supported by the U.S. Department of Defense (搜索) and Medical CBRN Defense Consortium (搜索), reflecting its strategic importance for national biodefense against a pathogen classified as a potential bioterrorism agent.
HDT Bio Corporation (搜索) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for HDT-321, marking a significant milestone in the development of the first clinical-stage prophylactic targeting Crimean-Congo Hemorrhagic Fever (搜索) (CCHF (搜索)). The Seattle-based clinical-stage biotechnology company received the clearance on September 19, 2025, enabling the advancement of this first-in-class product designed to protect against a fast-spreading, often fatal viral tick-borne disease (搜索).
Novel Platform Technology Shows Promise
HDT-321 represents the first clinical-stage product targeting CCHF (搜索) to utilize HDT Bio's immune stimulator platform. The formulation combines the company's proprietary LION™ delivery system (搜索) with new discoveries specific to CCHF. This platform demonstrated strong immune activation and a favorable safety profile during HDT's COVID-19 program, HDT-301, which resulted in regulatory emergency-use authorization of two vaccine products in India.
The product was developed through collaboration with the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIH/NIAID (搜索)) and the University of Texas Medical Branch (UTMB (搜索)). Under a Cooperative Research and Development Agreement between NIAID and UTMB, pre-clinical testing was conducted by the Laboratory of Virology at NIAID's Rocky Mountain Laboratories in Montana, where researchers demonstrated that HDT-321 could protect against CCHF (搜索) in several animal models.
Strategic National Security Implications
The development of HDT-321 is supported by the Medical CBRN Defense Consortium (搜索) and the U.S. Department of Defense (搜索), reflecting the product's strategic relevance to national biodefense. The threat posed by CCHF (搜索) to U.S. forces was underscored in 2009 when a U.S. soldier in Afghanistan died after contracting the disease, and several hospital staff in Germany who treated that patient were also infected.
"This IND clearance marks a major milestone for HDT Bio's ability to field homegrown, next-generation technologies against global biological threats," said Dr. Steve Reed, Chief Executive Officer of HDT Bio. "HDT-321 is a first-in-class product built on a best-in-class American platform. It is non-viral, scalable, deployable without cold-chain infrastructure, and, most importantly, the platform was well tolerated under previous clinical investigations."
Growing Global Health Threat
CCHF (搜索) is a viral illness spread by ticks and contact with infected animals, with mortality rates that can reach 40%. The NIAID (搜索) agency within the U.S. Department of Health and Human Services lists the CCHF virus as a priority pathogen and an emerging infectious disease of concern. The Centers for Disease Control and Prevention classifies it as a potential bioterrorism agent and a "Select Agent" due to biosecurity risks, while the World Health Organization considers it a top-priority pathogen because of its outbreak potential and the lack of approved treatments or vaccines.
The disease represents one of the most widespread viral hemorrhagic fevers in the world and continues to appear in new regions. In 2024 and 2025, confirmed cases in Portugal and Spain prompted the United Kingdom government to issue travel advisories. Climate change and expanding tick habitats are driving increased incidence across Eastern Europe, the Middle East, and Central Asia, raising concern about future outbreaks in the United States.
Legislative Support and National Strategy
Tick-borne diseases have drawn bipartisan concern in recent years, leading to the Kay Hagan Tick Act, named for Congresswoman Kay Hagan, who died from a tick-borne virus in 2019. The law established a coordinated national strategy to address high-consequence pathogens like CCHF (搜索). The Trump administration has reinforced that commitment by prioritizing biodefense, domestic manufacturing, and rapid-response technologies, aligning with HDT Bio's mission and highlighting the importance of American-made, field-ready tools like HDT-321 in protecting public health and national security.